This guide provides tips to help you draft an appeal letter. As of now, no relevant role in IgE in dermographism has been proven. Go to the nearest emergency room right away if you have any of these symptoms of an allergic reaction: Your healthcare provider will monitor you closely for symptoms of an allergic reaction while you are receiving XOLAIR and for a period of time after your injection. 2 . Use this cover sheet when faxing documents to XOLAIR Access Solutions. necessity. This form contains multiple pages. It is classified as a type of physical urticaria. Use Limitations of Use: XOLAIR is not indicated for treatment of other forms of urticaria. and insect bites and stings. prescription medicine, given under the skin by a nurse or doctor, that H1 antihistamines are a type of know if your hive condition is CIU, these discussion guides can help Referrals to Independent Co-pay Assistance Foundations, Referrals to the Genentech Patient Foundation, Herceptin HYLECTA™ (trastuzumab and hyaluronidase-oysk), PHESGO™ (pertuzumab, trastuzumab, and hyaluronidase-zzxf), PULMOZYME® (dornase alfa) Inhalation Solution, RITUXAN HYCELA® (rituximab/hyaluronidase human), XOLAIR® (omalizumab) for subcutaneous use, Rituxan® (rituximab) for Rheumatoid Arthritis (RA), Rituxan® (rituximab) for Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA), Rituxan® (rituximab) for Pemphigus Vulgaris (PV), Formulario de Consentimiento del Paciente Respiratorio. Genentech USA, Inc. and Novartis Pharmaceuticals Corporation make no representation as to the accuracy of the information contained on sites we do not own or control. Pharmaceuticals Corporation. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. In CRSwNP, the safety and efficacy of Xolair in patients below the age of 18 years have not been established. Xolair® (Omalizumab) Prior Review Fax Form Initial Chronic Idiopathic Urticaria treatment Continued Chronic Idiopathic Urticaria treatment Answer the following questions regarding place of service. The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. controlled by H1 antihistamines. checkbox next to each file you would like to download from the list The Respiratory Patient Consent Form with CIU. of urticaria. Click "OK" if you are a U.S. healthcare professional. have symptoms of an allergic reaction after leaving the healthcare The reaction can occur life-threatening condition and can lead to death. swallowing, wheezing, shortness of breath, cough, chest tightness, or trouble breathing, low blood pressure, dizziness, fainting, rapid or weak heartbeat, anxiety, or feeling of “impending doom”, flushing, itching, hives, or feeling warm, swelling of the throat or tongue, throat tightness, hoarse voice, or trouble swallowing, have a latex allergy. These are not all the possible side effects of XOLAIR. closely for symptoms of an allergic reaction while you are receiving allergic reaction: Your healthcare provider will monitor you after the first dose, or after many doses. A severe allergic reaction called In patients with chronic hives, a blood test is not necessary to determine the dose or dosing frequency. Talk with your healthcare provider about the best way to feed your baby while you receive XOLAIR. sample letter is also included for your reference. by the drug name). in Genentech Access Solutions. Is this request for INITIATION or CONTINUATION of Xolair therapy? are pregnant or plan to become pregnant. appropriate treatment option, as well as support. Do not receive XOLAIR if you are allergic to omalizumab or any of the ingredients in XOLAIR. Xolair is not used to treat other allergic conditions, other forms of urticaria, acute bronchospasm or status asthmaticus. You may also report side effects to Genentech at (888) 835-2555 or Novartis Pharmaceuticals Corporation at (888) 669-6682. Pharmaceuticals Corporation and is intended for U.S. Healthcare and is a 1. day admitted patient 2. non-admitted patient 3. patient on discharge. Professionals only. 2 DOSAGE AND ADMINISTRATION It is used as an add-on to existing treatment in patients aged 12 years or over in whom treatment with an antihistamine does not work well enough; XOLAIR is not used to treat other forms Your healthcare Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. above then click Download Selected. You may not see improvement in your symptoms right away after XOLAIR treatment. Yes or No c) Has member tried H1-antihistamine therapy? Learn more about their journey from diagnosis to finding an Omalizumab is not indicated for treatment of other allergic conditions or other forms of urticaria. Xolair (omalizumab) **Check www.fepblue.org/formulary to confirm which medication is part of the patient’s benefit NOTE: Form must be completed in its entirety for processing Is this request for brand or generic? chronic idiopathic urticaria (CIU, chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with their current CIU medicines. A severe allergic reaction called anaphylaxis can happen when you receive XOLAIR. Your healthcare provider should talk to you about getting medical treatment if you have symptoms of an allergic reaction after leaving the healthcare provider’s office or treatment center. Chronic spontaneous urticaria (CSU) Xolair is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1 antihistamine treatment. Use this form to enroll your practice in the XOLAIR Recertification Chronic Idiopathic Urticaria (CIU) Xolair is indicated for the treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment. moderate to severe persistent asthma in patients 6 years of age or older whose asthma symptoms are not controlled by asthma medicines called inhaled corticosteroids These items are not available as a PBS benefit for in-patients of a hospital. want to discuss treatment options or not yet diagnosed and want to Yes Or No - If Yes, please provide drug name _____ 1.3 Chronic Idiopathic Urticaria (CIU) XOLAIR is indicated for the treatment of adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment. Anaphylaxis is a If you have questions, please call 800-310-6826. It may also occur right treats CIU in patients 12 years of age and older who are not Xolair must not be administered by the intravenous or intramuscular route. ©[YEAR] Genentech USA, Inc. and Novartis XOLAIR is not used to treat other forms of urticaria. Xolair 75 mg single-dose prefilled syringe: 1 syringe every 14 days Xolair 150 mg single-dose prefilled syringe: 2 syringes every 14 days Xolair 150mg powder for injection: 3 vials every 14 days B. Max Units (per dose and over time) [Medical Benefit]: Allergic Asthma 90 billable units every 14 days Chronic idiopathic urticaria replaces the Patient Consent Form. Solar urticaria (SU) is a rare condition in which exposure to ultraviolet or UV radiation, or sometimes even visible light, induces a case of urticaria or hives that can appear in both covered and uncovered areas of the skin. This guide provides tips to help you draft a letter of medical Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis has occurred after the first dose of Xolair but also has occurred beyond 1 year after beginning treatment. It is unclear why Xolair has strong effects in disease activity in dermographism. The Prescriber Service Form and the Sign a printed form, take a photo and text it to (650) 877-1111 Sign a printed form and fax or mail it to us (or give it to your doctor's office to do so) Your doctor also has to fill out a form called the Prescriber Service Form. Respiratory Patient Consent Form are required for enrollment of the throat or tongue, throat tightness, hoarse voice, or trouble The needle cap on the XOLAIR prefilled syringe may contain latex, have ever had a severe allergic reaction called anaphylaxis. Chronic idiopathic urticaria (CIU; chronic hives without a known cause) in patients 12 years of age and older who continue to have hives that are not controlled by H1 antihistamine treatment. Anaphylaxis has occurred as early as after the first dose of Xolair, but also has occurred beyond 1 year after beginning regularly administered treatment. Patient Foundation: For more information, visit GenentechPatientFoundation.com. All rights reserved. .zip file. The information contained in this section of the site is intended for U.S. healthcare professionals only. Genentech does not recommend and does not endorse the content on any third-party websites. medicine used to treat allergic reactions such as hay fever, hives, cough, chest tightness, or trouble breathing, low blood pressure, dizziness, fainting, Watch the stories of people like you living you get going. FIND OUT MORE ABOUT XOLAIR Respiratory Patient Consent Form (to be completed by the patient). Please select answer below: Chronic idiopathic urticaria in adults and adolescents (12 years and older) who remain symptomatic despite H1 antihistamine treatment. We've made enrollment simpler, faster and more intuitive with some The classification of disease types is somewhat controversial. This site is intended for U.S. residents only. All rights reserved. The Genentech Patient Foundation gives free medicine to people who 2) Indicated for chronic idiopathic urticaria (CIU) in patients who remain symptomatic despite H1 antihistamine treatment. Do not decrease or stop taking any of your other hive medicine unless your healthcare providers tell you to. Request for Prior Authorization for Xolair (omalizumab) ... Coverage may be provided with a diagnosis of chronic idiopathic urticaria and the following criteria is met and the following criteria is met: The member is at least 12 years of age Must be prescribed by, or in consultation with, an … The supplied XOLAIR lyophilized powder must be reconstituted with Sterile Water for Injection (SWFI) USP, using the following instructions: 1) Before reconstitution, determine the number of vials that will need to be reconstituted (each vial delivers 150 mg of XOLAIR in 1.2 mL) (see Table 5). Xolair is not used to treat other allergic conditions, other forms of … Severe allergic reaction. hives, or feeling warm, swelling Two forms are needed to enroll in the Genentech Solar urticaria is a rare inducible (physical) urticaria caused by exposure to light. eligibility criteria. Important Safety Information. Read the full Medication Guide to learn more. The link you have selected will take you away from this site to one that is not owned or controlled by Genentech USA, Inc or Novartis Pharmaceuticals Corporation. It is not known if XOLAIR passes into your breast milk. Doses of more than 150 mg (Table 1) should be divided across two or more injection sites. XOLAIR is not used to treat other allergic conditions, other forms of hives, or sudden breathing problems. Section A –Member Information First Name: Last Name: Member ID: Sign up for relevant information to help Approximately 460,000 patients have been treated in the U.S. with Xolair since its initial approval for allergic asthma in 2003. provider should talk to you about getting medical treatment if you to find additional information to enclose in your letter. XOLAIR is a once-monthly injectable FDA approval letter (Follow this link and search provider’s office or treatment center. Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. Click "OK" if you are a healthcare professional. Urticaria is a very frequent skin condition characterised by transient wheal and flare type skin reactions associated with severe pruritus. https://www.verywellhealth.com/xolair-for-the-treatment-of-chronic-hives-83243 150-300 mg SC q4weeks. There are current case reports showing Xolair can help in other forms of physical urticaria such as cold, pressure and solar. Because of the risk of anaphylaxis, healthcare providers administering Xolair should Severe allergic reaction. What is XOLAIR? start the conversation between you and your specialist. Call your doctor for medical advice about side effects. It is not indicated for other allergic conditions or other forms of urticaria. Anaphylaxis, presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of Xolair. emergency room right away if you have any of these symptoms of an This item is only available to a patient who is attending: 1. an approved private hospital 2. a public participating hospital 3. a public hospital. XOLAIR should be given by your healthcare provider, in a healthcare setting. Documents will be downloaded as a XOLAIR is not used to treat other forms of urticaria. Treatment of solar urticaria may be challenging. To download multiple files at once, select the the links below to find additional information to enclose in your letter. XOLAIR and for a period of time after your injection. XOLAIR® (omalizumab) for subcutaneous use is an injectable prescription medicine used to treat adults and children 12 years of age and older with chronic idiopathic urticaria (CIU; chronic hives without a known cause) who continue to have hives that are not controlled by H1 antihistamine treatment. Please complete all pages to avoid a delay in our decision. Urticaria a) Is the urticaria chronic (continuously or intermittently present for at least 6 weeks)? It may also occur right after a XOLAIR injection or days later. Xolair PRIOR AUTHORIZATION REQUEST FORM Please complete this entire form and fax it to: 866-940-7328. ALTERNATIVE AGENTS/TREATMENTS Select a disease state for Rituxan® (rituximab). key changes to our forms. Brand Generic 1. XOLAIR is not used to treat other allergic conditions, other forms of hives, or sudden breathing problems. notifications. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, or herbal supplements. Two forms are needed to enroll in the Genentech Patient Foundation: Prescriber Foundation Form (to be completed by the health care provider). The Access Solutions logo is a registered don't have insurance or who have financial concerns and meet Xolair (omalizumab) is not indicated for the treatment of other forms of urticaria. Please see full Prescribing Information, including Medication Guide for additional Important Safety Information. The information contained in this section of the site is intended for U.S. healthcare professionals only. Xolair is also approved for chronic idiopathic urticaria in adults and adolescents (12 years of age and above) who remain symptomatic despite H. 1. antihistamine treatment. This website is a service of Genentech USA, Inc. and Novartis Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of XOLAIR. Anaphylaxis presenting as bronchospasm, hypotension, syncope, urticaria, and/or angioedema of the throat or tongue, has been reported to occur after administration of Xolair. Reminder Program for patient prior authorization reminder M-US-00002815(v1.0) 4/20. Download the forms you need to get started. A sample letter is also included for your reference. Go to the nearest Anaphylaxis is a life-threatening condition and can lead to death. Read the full Medication Guide to learn more. are breastfeeding or plan to breastfeed. For more information, visit GenentechPatientFoundation.com. Limitation of Use: Xolair is not indicated for treatment of other forms of urticaria. Allow at least 24 hours for review. Genentech and Novartis do not recommend or do not endorse the content on any third-party websites. after a XOLAIR injection or days later. In vitro, omalizumab forms complexes of limited size with IgE. Once we have both these forms, we can begin working with you and your doctor's office. Xolair is also used to treat: chronic (long-term) spontaneous urticaria (itchy rash). The reaction can occur after the first dose, or after many doses. © 2021 Genentech USA, Inc. and Novartis Pharmaceuticals Corporation. Xolair 75 mg single-dose prefilled syringe: 1 syringe every 14 days Xolair 150 mg single-dose prefilled syringe: 2 syringes every 14 days Xolair 150mg powder for injection: 3 vials every 14 days B. Max Units (per dose and over time) [Medical Benefit]: Allergic Asthma … A chronic idiopathic urticaria (CIU, chronic hives without a known cause) in people 12 years of age and older who continue to have hives that are not controlled with their current CIU medicines. The hospital provider name and number must be included on the application form. It is not known if XOLAIR may harm your unborn baby. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Chronic Idiopathic Urticaria. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites. Some patients have to completely avoid outdoor activities, which has a severe impact on their quality of life. What is the most important information I should know about XOLAIR? trademark of Genentech, Inc. Fill in the appropriate response: Y = Yes ; N = No; NA = Not Applicable • Chronic Idiopathic Urticaria Adults and adolescents 12 years of age and older with chronic idiopathic urticaria who remain symptomatic despite H1 antihistamine treatment. Dosing in CIU patients is not dependent on serum IgE level or body weight. Method of administration For subcutaneous administration only. Whether you’ve been diagnosed with CIU and anaphylaxis can happen when you receive XOLAIR. DOSAGE AND ADMINISTRATION 2.1 Published online: March 20, 2018. doom", flushing, itching, wheezing, shortness of breath, Yes or No b) Is the urticaria idiopathic (of unknown cause)? Use the links below Anaphylaxis has occurred as early as after the first dose of XOLAIR, but also has occurred beyond 1 year after beginning regularly administered treatment. H1 antihistamines are a type of medicine used to treat allergic reactions such as hay fever, hives, and insect bites and stings. XOLAIR is given in 1 or more injections under the skin (subcutaneous), 1 time every 4 weeks. rapid or weak heartbeat, anxiety, or feeling of "impending • Nasal Polyps